Back to Search
LIA GORE, MD
MD
Pediatric Hematology & Oncology Physician
NPI: 1649355389Individual
Specialties, Licenses & Credentials
Pediatric Hematology & Oncology PhysicianPrimary
Pediatrics — Pediatric Hematology-Oncology
Code: 2080P0207X
34722(CO)
Research & Publications (20)
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
PMID 18985740·Pediatr Blood Cancer·2009
2-rct
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
PMID 18579665·Clin Cancer Res·2008
3-trial
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
PMID 16980604·Ann Oncol·2006
3-trial
Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect?
PMID 18086346·Semin Oncol·2007
5-case
Long-term survival after intralesional resection and multi-modal therapy of thoracic spine osteosarcoma.
PMID 12692814·Med Pediatr Oncol·2003
5-case
Pediatric hematology-oncology fellowship training: new paradigms for the 21st century.
PMID 11603872·J Cancer Educ·2001
8-other
Protean clinical manifestations in children with leukemias containing MLL-AF10 fusion.
PMID 11187895·Leukemia·2000
5-case
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
PMID 19652058·J Clin Oncol·2009
3-trial
PARP1 expression in pediatric central nervous system tumors.
PMID 19533660·Pediatr Blood Cancer·2009
8-other
The National Report Card on the State of Emergency Medicine: evaluating the emergency care environment state by state 2009 edition.
PMID 19111195·Ann Emerg Med·2009
8-other
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
PMID 18618082·Invest New Drugs·2009
3-trial
Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors.
PMID 18985717·Pediatr Blood Cancer·2009
8-other
A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.
PMID 18509645·Cancer Chemother Pharmacol·2009
8-other
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.
PMID 18320191·Cancer Chemother Pharmacol·2008
3-trial
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
PMID 19074845·Mol Cancer Ther·2008
3-trial
Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.
PMID 18928662·Curr Oncol Rep·2008
6-review
Oncogenic and angiogenic growth factors accumulate during routine storage of apheresis platelet concentrates.
PMID 18559616·Clin Cancer Res·2008
8-other
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
PMID 18390968·J Clin Oncol·2008
3-trial
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
PMID 18058098·Cancer Chemother Pharmacol·2008
3-trial
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
PMID 18043132·Anticancer Drugs·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 13123 E 16TH AVE
AURORA, CO 80045 - Phone
- (720) 777-1234
Quick Facts
- NPI
- 1649355389
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile